1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>United Kingdom

Brexit Talks Must Prioritize Patient Access, Avoid Regulatory Divergence – EFPIA

European industry federation says patient access to new drugs must be a priority in the negotiations over the UK's exit from the EU, as must the need to ensure that the UK and EU drug regulatory systems don't diverge.

The European pharmaceutical industry federation EFPIA says that the interests of the patient and access to medicines must remain at the centre of any decisions taken in the context of negotiations over the UK's exit from the EU, and that the United Kingdom and European Union drug regulatory systems must not be allowed to diverge.

The association also expressed concern over the cloud of uncertainty now gathering over investment decisions and business planning.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

Scientists Work With AI To Uncover ‘Unexpected’ Drug Combos for Breast Cancer

 
• By Natasha Barrow

A UK research team has used artificial intelligence to find new treatments for cancer using existing US Food and Drug Administration-approved medicines that are not normally not used for the disease.

UK And US Regulators In Sync On RWD External Control Arms

 
• By Vibha Sharma

The UK regulator’s draft guideline on the use of external control arms based on real-world data reflects concepts similar to those outlined by the US Food and Drug Administration.

Why Hympavzi Secured English Funding For Hemophilia B But Not Hemophilia A

 
• By Neena Brizmohun

Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.

ClinicalTrials.gov Or ISRCTN: Getting Transparency Right For UK Trials

 
• By Vibha Sharma

ISRCTN’s systems are being redesigned to facilitate compliance with upcoming requirements in the UK’s clinical trials legislation.

More from Europe